Share this video  

ESMO 2019 | FIGHT-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma

Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the FIGHT-202 study (EudraCT: 2016-002422-36) of pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.